Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nystatin + silver sulfadiazine is a topical antimicrobial combination used primarily for the prevention and treatment of burn wound infections. This combination provides broad-spectrum coverage against both bacterial and fungal pathogens. Silver sulfadiazine is an antibacterial agent from the sulfonamide group that is effective against many gram-positive and gram-negative bacteria, while nystatin is an antifungal agent effective against Candida species. In vitro studies have shown that when combined in a 1:1 ratio, both agents maintain their antimicrobial properties without antagonism, unlike some other combinations (such as nystatin with Sulfamylon). This combination has been used successfully in clinical settings to control both local and systemic Candida and bacterial burn wound sepsis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nystatin + silver sulfadiazine.